Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ensartinib vs Crizotinib in ALK-positive NSCLC
NCT02767804Phase 3Active, not recruiting
- Sponsor
- Xcovery
- Start
- Jun 2016
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 20
01
Overview
A Phase 3 trial of ensartinib in non-small cell lung cancer (NSCLC), sponsored by Xcovery. Started Jun 2016; status: active, not recruiting.
02
Drugs
ensartinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02767804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02767804.